The role of mycophenolate mofetil in the management of autoimmune hepatitis and overlap syndromes

Alimentary Pharmacology and Therapeutics

Volumn 34, Issue 3, 2011, Pages 335-343

  Baven Pronk, A M C ^a   Coenraad, M J ^a   Van Buuren, H R ^b   De Man, R A ^b   Van Erpecum, K J ^c   Lamers, M M H ^d   Drenth, J P H ^d   Van Den Berg, A P ^e   Beuers, U H ^f   Den Ouden, J ^g   Koek, G H ^h   Van Nieuwkerk, C M J ⁱ   Bouma, G ⁱ   Brouwer, J T ^j   Van Hoek, B ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b ERASMUS MEDICAL CENTER   (Netherlands)

^c UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^d RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^e UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^f ACADEMIC MEDICAL CENTER   (Netherlands)

^g HAGA HOSPITAL   (Netherlands)

^h MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

ⁱ VU UNIVERSITY AMSTERDAM   (Netherlands)

^j REINIER DE GRAAF HOSPITAL   (Netherlands)

more..

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISOLONE;

ADOLESCENT; ADULT; AGED; ALOPECIA; ARTHRALGIA; ARTICLE; AUTOIMMUNE DISEASE; AUTOIMMUNE HEPATITIS; CHILD; CLINICAL ARTICLE; CONCENTRATION LOSS; CONTROLLED STUDY; DISEASE COURSE; DRUG EFFICACY; DRUG ERUPTION; DRUG FEVER; DRUG RESPONSE; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; FATIGUE; FEMALE; GASTROINTESTINAL SYMPTOM; HEART PALPITATION; HEMOLYTIC ANEMIA; HEPATITIS; HUMAN; INFECTION; ISCHEMIC COLITIS; LEUKOPENIA; LIVER CIRRHOSIS; MALE; MYALGIA; OBSERVATIONAL STUDY; OVERLAP SYNDROME; PANCREATITIS; PRIORITY JOURNAL; REMISSION; RETROSPECTIVE STUDY; SCHOOL CHILD; SIDE EFFECT; SKIN CARCINOMA;

ADOLESCENT; ADULT; AGED; CHILD; COHORT STUDIES; FEMALE; HEPATITIS, AUTOIMMUNE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; MYCOPHENOLIC ACID; NETHERLANDS; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; SYNDROME; TREATMENT OUTCOME; YOUNG ADULT;

EID: 79959943434     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2011.04727.x     Document Type: Article

References (40)

1. Czaja AJ,. Current concepts in autoimmune hepatitis. Ann Hepatol 2005; 4: 6-24.
2. Alvarez F, Berg PA, Bianchi FB, et al. International Autoimmune Hepatitis Group Report: review of criteria for diagnosis of autoimmune hepatitis. J Hepatol 1999; 31: 929-38. (Pubitemid 29514229)
3. Krawitt EL,. Autoimmune hepatitis. N Engl J Med 2006; 354: 54-66. (Pubitemid 43048951)
4. Hennes EM, Zeniya M, Czaja AJ, et al. Simplified criteria for the diagnosis of autoimmune hepatitis. Hepatology 2008; 48: 169-76. (Pubitemid 351975541)
5. Johnson PJ, McFarlane IG,. Meeting report: International Autoimmune Hepatitis Group. Hepatology 1993; 18: 998-1005.
6. Boberg KM,. Prevalence and epidemiology of autoimmune hepatitis. Clin Liver Dis 2002; 6: 635-47.
7. Soloway RD, Summerskill WH, Baggenstoss AH, et al. Clinical, biochemical, and histological remission of severe chronic active liver disease: a controlled study of treatments and early prognosis. Gastroenterology 1972; 63: 820-33.
8. Czaja AJ, Freese DK,. AASLD practice guidelines: diagnosis and Treatment of Autoimmune Hepatitis. Hepatology 2002; 36: 479-97. (Pubitemid 34810370)
9. Cook GC, Mulligan R, Sherlock S,. Controlled prospective trial of corticosteroid therapy in active chronic hepatitis. Q J Med 1971; 40: 159-85.
10. Summerskill WH, Korman MG, Ammon HV, Baggenstoss AH,. Prednisone for chronic active liver disease: dose titration, standard dose, and combination with azathioprine compared. Gut 1975; 16: 876-83.
11. Murray-Lyon IM, Stern RB, Williams R,. Controlled trial of prednisone and azathioprine in active chronic hepatitis. Lancet 1973; 1: 735-7.
12. Tage-Jensen U, Schlichting P, Aldershvile J, et al. Azathioprine versus prednisone in non-alcoholic chronic liver disease (CLD). Relation to a serological classification. Liver 1982; 2: 95-103. (Pubitemid 12037186)
13. Stellon AJ, Hegarty JE, Portmann B, Williams R,. Randomised controlled trial of azathioprine withdrawal in autoimmune chronic active hepatitis. Lancet 1985; 1: 668-70. (Pubitemid 15134821)
14. Lamers MM, van Oijen MG, Pronk M, Drenth JP,. Treatment options for autoimmune hepatitis: a systematic review of randomized controlled trials. J Hepatol 2010; 53: 191-8.
15. Czaja AJ,. Treatment strategies in autoimmune hepatitis. Clin Liver Dis 2002; 6: 799-824.
16. Vierling JM, Flores PA,. Evolving new therapies of autoimmune hepatitis. Clin Liver Dis 2002; 6: 825-50, ix.
17. Larsen FS, Vainer B, Eefsen M, Bjerring PN, Adel Hansen B,. Low-dose tacrolimus ameliorates liver inflammation and fibrosis in steroid refractory autoimmune hepatitis. World J Gastroenterol 2007; 13: 3232-6. (Pubitemid 47064587)
18. Alvarez F, Ciocca M, Canero-Velasco C, et al. Short-term cyclosporine induces a remission of autoimmune hepatitis in children. J Hepatol 1999; 30: 222-7. (Pubitemid 29071183)
19. Fernandes NF, Redeker AG, Vierling JM, Villamil FG, Fong TL,. Cyclosporine therapy in patients with steroid resistant autoimmune hepatitis. Am J Gastroenterol 1999; 94: 241-8. (Pubitemid 29063476)
20. Aqel BA, Machicao V, Rosser B, Satyanarayana R, Harnois DM, Dickson RC,. Efficacy of tacrolimus in the treatment of steroid refractory autoimmune hepatitis. J Clin Gastroenterol 2004; 38: 805-9. (Pubitemid 39274185)
21. Burak KW, Urbanski SJ, Swain MG,. Successful treatment of refractory type 1 autoimmune hepatitis with methotrexate. J Hepatol 1998; 29: 990-3. (Pubitemid 28559070)
22. de Boer NK, van Nieuwkerk CM, Aparicio Pages MN, de Boer SY, Derijks LJ, Mulder CJ,. Promising treatment of autoimmune hepatitis with 6-thioguanine after adverse events on azathioprine. Eur J Gastroenterol Hepatol 2005; 17: 457-61. (Pubitemid 40477518)
23. Pratt DS, Flavin DP, Kaplan MM,. The successful treatment of autoimmune hepatitis with 6-mercaptopurine after failure with azathioprine. Gastroenterology 1996; 110: 271-4. (Pubitemid 26021628)
24. Richardson PD, James PD, Ryder SD,. Mycophenolate mofetil for maintenance of remission in autoimmune hepatitis in patients resistant to or intolerant of azathioprine. J Hepatol 2000; 33: 371-5. (Pubitemid 30663373)
25. Devlin SM, Swain MG, Urbanski SJ, Burak KW,. Mycophenolate mofetil for the treatment of autoimmune hepatitis in patients refractory to standard therapy. Can J Gastroenterol 2004; 18: 321-6. (Pubitemid 38801788)
26. Chatur N, Ramji A, Bain VG, et al. Transplant immunosuppressive agents in non-transplant chronic autoimmune hepatitis: the Canadian association for the study of liver (CASL) experience with mycophenolate mofetil and tacrolimus. Liver Int 2005; 25: 723-7. (Pubitemid 41038652)
27. Czaja AJ, Carpenter HA,. Empiric therapy of autoimmune hepatitis with mycophenolate mofetil: comparison with conventional treatment for refractory disease. J Clin Gastroenterol 2005; 39: 819-25. (Pubitemid 41361901)
28. Inductivo-Yu I, Adams A, Gish RG, et al. Mycophenolate mofetil in autoimmune hepatitis patients not responsive or intolerant to standard immunosuppressive therapy. Clinical Gastroenterol Hepatol 2007; 5: 799-802. (Pubitemid 47031057)
29. Hlivko JT, Shiffman ML, Stravitz RT, et al. A single center review of the use of mycophenolate mofetil in the treatment of autoimmune hepatitis. Clinical Gastroenterol Hepatol 2008; 6: 1036-40.
30. Hennes EM, Oo YH, Schramm C, et al. Mycophenolate mofetil as second line therapy in autoimmune hepatitis? Am J Gastroenterol 2008; 103: 3063-70.
31. Wolf DC, Bojito L, Facciuto M, Lebovics E,. Mycophenolate mofetil for autoimmune hepatitis: a single practice experience. Dig Dis Sci 2009; 54: 2519-22.
32. Aw MM, Dhawan A, Samyn M, My Bargiota A, Mieli-Vergani G,. Mycophenolate mofetil as rescue treatment for autoimmune liver disease in children: a 5-year follow-up. J Hepatol 2009; 51: 156-60.
33. Sharzehi K, Huang MA, Schreibman IR, Brown KA,. Mycophenolate mofetil for the treatment of autoimmune hepatitis in patients refractory or intolerant to conventional therapy. Can J Gastroenterol 2010; 24: 588-92.
34. Rust C, Beuers U,. Overlap syndromes among autoimmune liver diseases. World J Gastroenterol 2008; 14: 3368-73.
35. Chazouilleres O, Wendum D, Serfaty L, Montembault S, Rosmorduc O, Poupon R,. Primary biliary cirrhosis-autoimmune hepatitis overlap syndrome: clinical features and response to therapy. Hepatology 1998; 28: 296-301. (Pubitemid 28363652)
36. Gohlke F, Lohse AW, Dienes HP, et al. Evidence for an overlap syndrome of autoimmune hepatitis and primary sclerosing cholangitis. J Hepatol 1996; 24: 699-705. (Pubitemid 26226666)
37. Manns MP, Czaja AJ, Gorham JD, et al. Diagnosis and management of autoimmune hepatitis. Hepatology 2010; 51: 2193-213.
38. Dharancy S, Iannelli A, Hulin A, et al. Mycophenolate mofetil monotherapy for severe side effects of calcineurin inhibitors following liver transplantation. Am J Transplant 2009; 9: 610-3.
39. Dandel M, Jasaityte R, Lehmkuhl H, Knosalla C, Hetzer R,. Maintenance immunosuppression with mycophenolate mofetil: long-term efficacy and safety after heart transplantation. Transplant Proc 2009; 41: 2585-8.
40. Manns MP, Woynarowski M, Kreisel W, et al. Azathioprine with budesonide induces remission more effectively than with prednisone in patients with autoimmune hepatitis. Gastroenterology 2010; 139: 1198-206.